Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Acceleron Pharma (XLRN) Share Price

Share on StockTwits

News coverage about Acceleron Pharma (NASDAQ:XLRN) has been trending somewhat positive on Saturday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Acceleron Pharma earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.3411050449548 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Acceleron Pharma traded up $0.32, hitting $37.37, on Friday, MarketBeat.com reports. 635,275 shares of the company’s stock were exchanged, compared to its average volume of 297,202. The stock has a market cap of $1.70 billion, a P/E ratio of -13.94 and a beta of 1.44. Acceleron Pharma has a 1-year low of $29.35 and a 1-year high of $46.93.

Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.64) by $0.06. The business had revenue of $3.23 million during the quarter, compared to analysts’ expectations of $3.77 million. Acceleron Pharma had a negative return on equity of 34.52% and a negative net margin of 839.98%. The business’s quarterly revenue was down 12.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.66) EPS. research analysts forecast that Acceleron Pharma will post -2.38 EPS for the current fiscal year.

XLRN has been the topic of several recent research reports. JPMorgan Chase & Co. upgraded Acceleron Pharma from a “neutral” rating to an “overweight” rating and set a $33.00 price target on the stock in a report on Monday, February 26th. Piper Jaffray Companies upped their price objective on Acceleron Pharma to $53.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 28th. HC Wainwright reaffirmed a “buy” rating and set a $62.00 price objective on shares of Acceleron Pharma in a research report on Wednesday, February 28th. Barclays upped their price objective on Acceleron Pharma from $50.00 to $54.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 28th. Finally, Citigroup upped their price objective on Acceleron Pharma from $44.00 to $63.00 and gave the stock a “positive” rating in a research report on Thursday, March 1st. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $50.89.

In related news, EVP Matthew L. Sherman sold 4,600 shares of the company’s stock in a transaction dated Tuesday, April 3rd. The stock was sold at an average price of $38.43, for a total value of $176,778.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kevin F. Mclaughlin sold 4,000 shares of the company’s stock in a transaction dated Tuesday, April 3rd. The shares were sold at an average price of $38.45, for a total value of $153,800.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 9,804 shares of company stock valued at $376,812. Insiders own 3.90% of the company’s stock.

Acceleron Pharma Company Profile

Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply